Olaparib in treatment of men with mCRPC and selected HRR gene mutations

According to a media release issued by AstraZeneca and Merck on Friday evening, olaparib (Lynparza) has shown “a statistically significant and clinically meaningful improvement in … overall survival (OS)” in men with metastatic, castration-resistant prostate cancer (mCRPC) and BRCA1/2 or ATM gene mutations (homologous repair gene mutations or HRRm). … READ MORE …

Data from the PROfound trial reported at ESMO

From a report presented by Hussain yesterday at the annual meeting of the European Society for Medical Oncology (ESMO) we gained detailed insight into the results of the PROfound trial of olaparib (Lynparza), which had been said to be positive last August. … READ MORE …

Is PTEN loss a risk factor for progression of men on active surveillance?

A newly published paper in the journal Prostate Cancer and Prostatic Diseases has explored the above question based on data from the Johns Hopkins active surveillance (AS) cohort of men with initially low- or very low-risk prostate cancer. … READ MORE …

PSA velocity no better than latest PSA value in screening men carrying BRCA1/2 genes

Data from the ongoing, prospective IMPACT study has shown that PSA velocity is not predictive of risk for a positive prostate cancer biopsy result in men who are carriers of the BRCA2 gene. … READ MORE …

A possible future test to differentiate between risk for aggressive and indolent forms of prostate cancer

A new paper by an  international group of researchers from several different centers has maybe identified a new way to differentiate accurately between indolent and aggressive forms of prostate cancer at time of initial diagnosis. … READ MORE …

FDA approves CAR T-cell therapy for treatment of acute lymphoblastic leukemia

Within the past few hours, the US Food and Drug Administration (FDA) has approved the very first form of chimeric antigen receptor (CAR) T-cell therapy for the treatment of cancer — and this is also the first true form of gene therapy to be made available here in the US. … READ MORE …

Height IS a risk factor for higher-risk prostate cancer

A newly published and very detailed paper based on data from the PRACTICAL consortium now seems to have confirmed that taller men are at greater risk for high-risk prostate cancer than shorter ones (like your sitemaster). … READ MORE …